


Journal Pre-proof

Role of Pharmacists in the Care of Adult Asthma Patients: A Scoping Review

Aseel Mahmoud, Ahmad Y. Abuhelwa, Tom Owen, Amad Alazzawi, Mohd Shara, Mohammad A.Y. Alqudah, Maguy Saffouh ElHajj, Jane R. Smith



PII: S1551-7411(24)00196-7

DOI: <https://doi.org/10.1016/j.sapharm.2024.06.005>

Reference: RSAP 2297

To appear in: *Research in Social & Administrative Pharmacy*

Received Date: 30 November 2023

Revised Date: 4 April 2024

Accepted Date: 13 June 2024

Please cite this article as: Mahmoud A, Abuhelwa AY, Owen T, Alazzawi A, Shara M, Alqudah MAY, ElHajj MS, Smith JR, Role of Pharmacists in the Care of Adult Asthma Patients: A Scoping Review, *Research in Social & Administrative Pharmacy*, <https://doi.org/10.1016/j.sapharm.2024.06.005>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2024 Published by Elsevier Inc.

Role of Pharmacists in the Care of Adult Asthma Patients: A Scoping Review

Aseel Mahmoud^{1*}, Ahmad Y Abuhelwa^{2,3}, Tom Owen¹, Amad Alazzawi¹, Mohd Shara^{2,3}, Mohammad A Y Alqudah^{2,3,4}, Maguy Saffouh ElHajj⁵, Jane R Smith¹

1 Faculty of Health and Life Sciences, University of Exeter, Exeter, UK

2 Department of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates

3 Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates

4 Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, 22110, Jordan

5 College of Pharmacy, QU Health, Qatar University, Doha, Qatar

*Correspondence to Dr Aseel Mahmoud, a.mahmoud@exeter.ac.uk

Declaration of interests

The authors declare that they have no competing interests.

Authors' contributions

AM and TO conducted the data extraction and analysis. AM wrote the manuscript. All authors contributed to the interpretation of the data, provided critical review and revisions of the manuscript and provided final approval for the manuscript.

Funding

This work was supported by the University of Exeter Global MENA Development fund [MENA2.12-22-23, 2022] and matched in-kind support by the University of Sharjah.

1 **Role of Pharmacists in the Care of Adult Asthma Patients: A**

2 **Scoping Review**

3

4 Abstract

5 Background:

6 Asthma is a common long-term condition that affects people of all ages. Evidence suggests
7 that a significant proportion of asthma patients in the Gulf Cooperation Council (GCC) do not
8 receive appropriate diagnosis, monitoring and/or treatment. When inadequately treated,
9 asthma can negatively affect quality of life and may lead to hospitalisation and death. Although
10 pharmacists play a role in asthma care globally, there appears to be no defined role for
11 pharmacists in providing care to patients with asthma in the GCC countries.

12 Aim:

13 This scoping review aims to review and summarise studies conducted in the GCC countries
14 involving pharmacists in the management of adults with asthma or evaluating pharmacists'
15 asthma care knowledge and/or skills.

16 Method:

17 A systematic scoping review was undertaken. Seven databases were searched using relevant
18 search terms for articles published up to May 2023. Studies that evaluated pharmacists' roles,
19 knowledge and skills in providing asthma care to adults in the United Arab Emirates (UAE),
20 Qatar, Kuwait, Oman, Saudi Arabia, and Bahrain were considered eligible for inclusion.
21 Extracted data were collated using tables and used to produce narrative descriptive
22 summaries.

23 Results:

24 Out of the 1588 search results, only seven studies met the inclusion criteria. Of those, only
25 one developed and tested a pharmacist-led inhaler technique educational intervention in the
26 UAE within community pharmacy setting for asthma patients. The remaining six studies
27 assessed community pharmacists' knowledge in providing asthma management and patient
28 education in UAE, Saudi Arabia and Qatar. The quality of the included studies varied with four
29 relying on simulated patients to assess pharmacists' knowledge. The study that tested the
30 intervention suggested improvement in inhaler technique and asthma symptoms control after
31 receiving the intervention. The findings suggest a need to improve pharmacists' knowledge of
32 inhaler technique demonstration (mainly Metered Dose Inhalers), asthma management advice
33 and assessment of asthma control and medication use.

34 Conclusion:

35 This review highlights a lack of research on pharmacist-led asthma interventions and identifies
36 training needs to enable pharmacists to be involved in asthma care in the GCC countries.
37 Future research could develop approaches involving pharmacists to improve asthma care and
38 outcomes in the region.

39 Keywords: Pharmacy Practice, Gulf Countries, Asthma, Pharmacists' skillset.

40 Introduction

41 Asthma is a long-term condition (LTC) that is characterised by symptoms such as
42 breathlessness, chest tightness, coughing and wheezing, with acute exacerbations that can
43 be life-threatening^{1,2}. An estimated 235 million people live with asthma globally, and due to its
44 high prevalence, chronic nature and impacts on quality of life, asthma poses a significant
45 health concern^{1,2}. A systematic review conducted in 2009 found that asthma had a high
46 economic burden amongst LTCs³.

47 Although asthma is a major health problem, there is a lack of information on the prevalence of
48 asthma in the Middle East including the Gulf Cooperation Council (GCC)⁴, which includes the
49 six nations bordering the Persian Gulf namely: United Arab Emirates (UAE), Qatar, Bahrain,
50 Oman, Kingdom of Saudi Arabia (KSA), and Kuwait. According to a cross-sectional
51 epidemiological study in 2018, the estimated prevalence of asthma in adult patients in the
52 GCC countries is 7.6%, based on data collected from Saudi Arabia, Kuwait, and the UAE⁴.
53 Prevalence of asthma has been reported to range from 4.7% to 32.0% in studies that were
54 conducted in KSA, Kuwait, Bahrain, Oman, Qatar and the UAE between 1986 and 2017.
55 Asthma also causes a substantial economic burden⁵. In the gulf asthma costs (including
56 medications, hospitalisation, emergency visits and regular management) range from 23 million
57 to 208 million US dollars per year⁵. Furthermore, asthma exacerbations pose a burden on the
58 healthcare system because of the increasing rate of hospitalisation and emergency visits as
59 shown in the data from Kuwait and UAE^{5,6}.

60 Given the complex and episodic nature of asthma, innovative, multidisciplinary approaches
61 are needed to improve its management^{1,7,8}. Asthma care encompasses medication
62 management, education on asthma triggers and self-management techniques, and regular
63 monitoring and follow-up^{5,9,10}. Several guidelines for asthma care have been established
64 globally, such as the Global Initiative for Asthma Management (GINA)^{7,8,10}. These guidelines
65 offer recommendations for the diagnosis and monitoring of asthma, as well as both non-
66 pharmacological and pharmacological approaches to management. Pharmacological
67 management includes the utilization of reliever inhalers (Short-Acting Beta 2 Agonists (SABA))
68 and preventer inhalers (primarily Inhaled Corticosteroids (ICS))^{7,10}.

69 Notably, KSA, UAE, and Qatar have published their own specific asthma guidelines^{5,11-13}.
70 Additionally, to improve the outcomes in patients with asthma and other LTCs in the UAE, the
71 Ministry of Health launched "Ea'nah initiative", a program that aims to ensure permanent
72 access to treatment for patients with financial constraints¹⁴. In UAE there is a national
73 guideline for asthma management that was published by the Ministry of Health in 2013 and
74 local guidelines that were developed in 2018 by the Department of Health in Abu-Dhabi. Local
75 guidelines primarily focus on asthma diagnosis and management in adults and are tailored to
76 the healthcare delivery system in Abu Dhabi exclusively^{11,12}.

77 However, limited implementation of asthma guidelines in the GCC countries has hindered the
78 achievement of asthma management goals and the control of symptoms in patients^{5,6}. A high
79 proportion of asthma patients continue to experience poor symptom control and asthma
80 attacks⁶. There are notable disparities in the percentage of patients experiencing poorly
81 controlled asthma, ranging from 44% to 97% in various studies conducted across different
82 GCC countries between 2007 and 2018^{6,15-17}. These studies identified that poor asthma
83 control may be related to lack of knowledge about asthma management among patients and
84 healthcare professionals (HCPs), mainly the importance of the use of preventer inhalers in

85 asthma management ^{5,6,15-17}. Currently, some patients refuse to use controller inhalers and
86 some HCPs are unaware of the recent updates to GINA guidelines that recommend shifting
87 away from SABA-only treatment and using ICS containing preventer inhalers instead ^{5,6,8}.
88 Additionally, a failure to assess comorbidities such as obesity, allergic rhinitis,
89 gastroesophageal reflux and obstructive sleep apnoea and smoking status in asthma patients
90 in the Gulf region may further contribute to the high levels of poor asthma control ^{5,7,10}. As the
91 prevalence of these comorbidities is high and rising in the GCC countries, its negatively
92 affecting the burden of asthma ⁵.

93 Asthma care in the CCG countries may involve various HCPs, including general practitioners
94 (GPs), specialist pulmonary doctors, and nurses. However, the specific roles and
95 responsibilities of HCPs vary by country, region, or healthcare system. Asthma care is typically
96 provided in both outpatient and inpatient settings. Outpatient care may be provided at primary
97 healthcare centres or specialised clinics, while inpatient care may be provided at larger
98 hospitals. However, there appears to be no clearly defined role for pharmacists or pharmacies
99 in providing care to patients with LTCs including asthma in the GCC countries ¹⁸. This gap in
100 the utilization of pharmacists in asthma management and LTCs warrants further exploration
101 as addressing it has the potential to improve healthcare delivery and patient outcomes.

102 Pharmacists indeed play a role in asthma care globally ¹⁹. In an inpatient setting in the United
103 States (US), pharmacists may assess patients seeking care at emergency departments for an
104 exacerbation of asthma, their medication adherence or administration technique, patient-
105 specific concerns with respect to medication use, the need for modification of therapy, access
106 to medications at discharge, contraindicated medications and vaccinations if applicable ¹⁹.
107 Whereas, in an outpatient setting in the US, pharmacists provide education on self-
108 management of asthma ¹⁹. The role of pharmacists in the United Kingdom (UK), for instance,
109 has been continuously evolving towards providing asthma care to adult patients ²⁰. Within
110 primary care, patients may see a practice pharmacist to support long-term asthma
111 management ^{9,21,22}. In community pharmacy settings, pharmacists play a pivotal role by not
112 only dispensing prescriptions to asthma patients but also actively engaging in patient
113 education about medications and providing valuable advice, particularly in areas such as
114 smoking cessation ^{21,23-25}. Furthermore, community pharmacies contribute to the well-being of
115 asthma patients by offering essential services, including medication reviews and/or referrals
116 to their GP for comprehensive reviews, ensuring an increasingly coordinated approach to
117 asthma care ²⁵⁻²⁷. The expanding roles of pharmacists in the UK and the US serve as a
118 noteworthy example of how pharmacists can be instrumental in enhancing asthma care.

119 Published international studies demonstrated that pharmacist-led asthma interventions can
120 improve patient outcomes, including adherence and inhaler technique which improved asthma
121 control in the study participants ²⁸⁻³⁰. However, there is scarce evidence on the role of
122 pharmacists in asthma care in adult patients in the GCC countries ³¹. Therefore, the aim of
123 this scoping review is to provide an overview of studies conducted in the GCC countries
124 reporting on interventions where pharmacists were involved in the care of adults with asthma
125 or assessing pharmacists' skills and knowledge in providing asthma care.

126 The objectives were to describe:

- 127 1) The design and quality of the studies that reported on asthma interventions
128 involving pharmacists or tested pharmacists' skills and knowledge.
- 129 2) The type of interventions or initiatives provided by pharmacists to adult asthma
130 patients in included studies, key features of any interventions, the role of the
131 pharmacist in intervention provision and the training provided to pharmacists to
132 support delivery of the asthma intervention.

- 133 3) Aspects of pharmacists' knowledge and skills that were tested in included
 134 studies and how these were assessed.
 135 4) Any factors reported as affecting the implementation of asthma interventions or
 136 initiatives involving pharmacists.

137 **Methods**

138 This review followed a protocol that was developed by the research team in accordance with
 139 published guidance for scoping reviews³² and was reported using the Preferred Reporting
 140 Items for Systematic Reviews and Meta-Analysis Extension for Scoping Reviews (PRISMA-
 141 Scr) guidelines³³. Preliminary searches of each database were undertaken to identify relevant
 142 key words. These search terms underwent a collaborative review with our research team,
 143 which includes stakeholders based in the UAE (MS, MAYA) and AA (who previously practised
 144 in the UAE). Additionally, the search strategy was further honed with the invaluable input of an
 145 information specialist, who is a member of the South West Peninsula Applied Research
 146 Collaboration (PenARC) evidence synthesis team.

147 ***Literature search and screening***

148 Seven electronic databases were searched: Scopus, Cochrane Central Registers of
 149 Controlled Trials, Medline via PubMed, CINAHL, EMBASE, Global Health and PsycInfo via
 150 OVID platform. The literature search was conducted by AM to identify relevant articles
 151 published up to May 2023 using search terms identified from two related published reviews
 152^{28,30} Medline Medical Subject Heading (MeSH) terms Table 1 and preliminary searches of each
 153 database to identify relevant keywords (Table 1). The search strategy was reviewed and
 154 collaboratively developed by the research team, with input from an information specialist.

155 *Table 1 Key terms and search terms used in the literature search*

156	Key terms	Search word
157	<i>Pharmacy</i>	<ul style="list-style-type: none"> ▪ Pharmacy ▪ Pharmacist ▪ CHEMIST ▪
158	<i>Asthma</i>	<ul style="list-style-type: none"> ▪ Asthma
159	<i>Country</i>	<ul style="list-style-type: none"> ▪ Gulf ▪ MENA ▪ Middle East ▪ United Arab Emirates ▪ Qatar ▪ Kuwait ▪ Saudi Arabia ▪ Bahrain ▪ Oman ▪ Dubai ▪ Sharjah ▪ Abu-Dhabi ▪ Ajman ▪ Alain
160	<p>Boolean logic: (Pharmacy OR Pharmacist OR Chemist) AND Asthma AND (Gulf OR Middle East OR MENA OR United Arab Emirates OR Dubai OR Sharjah OR Abu-Dhabi OR Ajman OR Qatar OR Kuwait OR Saudi Arabia OR Bahrain OR Oman)</p>	

168

169 Reference lists of all the studies meeting the inclusion criteria were screened for additional
 170 studies.

171 ***Inclusion criteria***

172 This review focused on studies that evaluated asthma interventions or initiatives involving
173 pharmacists in any setting (e.g., community, primary or secondary care settings). Community
174 pharmacies were defined as either small independently owned shops, chain franchised shops,
175 or pharmacies affiliated with hospitals or medical centres^{18,31}.

176 Therefore, the inclusion criteria for this review were studies:

- 177 ▪ involving any intervention or initiative aimed at improving asthma management,
178 which was predominantly delivered by a pharmacist or in which pharmacists
179 played a substantial role.
- 180 ▪ focussed on asthma patients aged 18 years or older, or in which the focus was
181 primarily on adults.
- 182 ▪ reporting on experiences of adults with asthma or pharmacists in relation to
183 receiving or delivering asthma care where pharmacists were involved.
- 184 ▪ Studies assessing pharmacists' knowledge or skills in providing asthma care.

185 Studies of any type or design or using any methodology were included initially to map all
186 existing research involving pharmacists in the care of adult asthma patients in GCC countries.
187 Only original research papers written in English were included as it is the primary language
188 used for academic publications in the GCC countries, as advised by stakeholders. Published
189 conference abstracts and reviews were excluded and reviews were manually checked for
190 further references.

191 ***Exclusion criteria***

192 The focus was to maximise relevance, thus studies were excluded from consideration if:

- 193 • The focus of the studies was on children or if children were the main focus.
- 194 • The studied intervention or initiative primarily involved delivery or participation by any
195 health professional other than pharmacists, or if pharmacists played only a minor or
196 peripheral role, such as a non-patient-facing role (for example, identifying participants
197 only).
- 198 • They did not pertain to one of the GCC countries.
- 199 • Full text or an English version could not be obtained.

200 ***Study selection***

201 Following searching, citations were downloaded into EndNote®20, 2013 by Clarivate,
202 reference management software and duplicates were removed by TO. Screening of all study
203 titles and abstracts against the inclusion/exclusion criteria was performed by TO and then
204 second screened by another independent reviewer (AM, JS, AYA, AA). Any disagreements
205 were resolved through collaborative discussion with other members of the research team.
206 Subsequently, the full texts of the potentially relevant studies were downloaded into
207 EndNote®. These texts were independently assessed by TO and AM, and any divergences
208 were further discussed with the research team to determine the eligibility of articles for
209 inclusion.

210 ***Data extraction and analysis***

211 Data relating to country, setting, study design, sample size, population, any intervention
212 delivered, pharmacists' skills/knowledge assessed and key findings were extracted by TO and
213 double checked by AM for all included studies. To ensure consistency, a data extraction tool

214 was developed by the research team using Microsoft Excel based on published guidance for
215 scoping reviews ³². Any discrepancies were discussed and resolved through consensus.

216 **Quality assessment**

217 A formal assessment of the methodological quality of the studies was not conducted, as the
218 aim of the scoping review is to provide an overview and description of the available evidence.
219 Instead, the quality of the included studies was summarised in terms of study design, sample
220 size, strength and limitations.

221 **Results**

222 **Search results**

223 The search yielded a total of 1588 hits (Figure 1). After removal of duplicates and following
224 title and abstract screening, 38 full texts were assessed for eligibility. Among these, six studies
225 ³⁴⁻³⁹ met the inclusion criteria and one further study ⁴⁰ was manually identified from the
226 reference list of the screened full-text article. Only one study evaluated a pharmacist-led
227 asthma intervention, while the other six assessed pharmacists' knowledge or skills ³⁴. The
228 main reasons for exclusion were as follows: the study population did not consist solely of
229 asthma patients or included paediatric patients, the intervention provided was not fully
230 described, preventing determination of whether it was administered by a pharmacist, or the
231 full text could not be obtained.

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246


247

248

249

Figure 1 PRISMA flow diagram

250



251

252

253 Table 2 provides an overview of the studies' characteristics. There was one randomised control
 254 trial (RCT) of an intervention conducted in UAE ³⁴, one randomised cross-sectional study from
 255 Qatar utilising simulated patients (SP) and surveys ³⁷ and three observational studies (two
 256 conducted in KSA, one in UAE) ^{35,36,40} that used SP and two cross-sectional surveys
 257 undertaken in KSA ^{38,39}. Included studies were conducted across the three countries (UAE
 258 ^{34,36}, Qatar ³⁷ and KSA) ^{35,38-40} between 2013 and 2021³⁴⁻⁴⁰. Among the included studies; five
 259 ^{35-38,40} were conducted in community pharmacy, whereas two ^{34,39} were conducted across
 260 hospital and community pharmacy settings.

Study ID	Country	Study design	Setting	Study population	Sample size	Aim of the study	Outcomes measured and assessment method
<i>Basheti 2021</i> ³⁴	UAE	Single blinded RCT	Patients were recruited in hospital and the intervention was delivered in community pharmacy in Dubai	Asthma patients visiting a respiratory clinic and using a preventative inhaler	245 asthma patients (93 on TH, 70 ACC, 82 pressurised MDI)*	This study aimed to assess the effectiveness of inhaler technique labels incorporating the individual technique steps in image format on the retention of correct inhaler technique for patients with asthma and following inhaler training; secondly to investigate the effect of inhaler technique education using self-check image labels on patients' overall asthma control one-month post-intervention.	Patients were randomised into intervention and control groups and outcomes were measured at baseline and after one month of receiving the intervention. Inhaler technique assessment (the pharmacist assessed inhaler technique demonstrated by patients against a validated inhaler technique checklist), Asthma control (ACT) and lung function (PEF and FEV)**.
<i>Paravattil 2017</i> ³⁷	Qatar	Randomised cross-sectional study using simulated patients and survey. A simulated patient was randomly assigned to visit different community pharmacies and randomly selected for the prescription (50%) or refill scenario (50%) for asthma medication.	Private community pharmacies in Qatar	Registered pharmacists	65 pharmacists	The study aimed to explore counselling practices among community pharmacists in Qatar and to determine if patient counselling was influenced by patient, pharmacist, and pharmacy characteristics.	SP*** filled in a counselling form (developed based on competency standards for pharmacists) after the visit to the pharmacy. The form was used to calculate the counselling score that assessed the content provided to the SP by the pharmacist in terms of assessment of patient's medical history and medication use and information provided that is specific to asthma medication.
<i>Adnan 2015</i> ³⁵	KSA	Observational study using SP. SP presented to the pharmacy asking to train them to use MDI.	Community pharmacies in Al-Qasim region	Registered pharmacists	96 Pharmacists	The study aimed to assess the ability of community pharmacists to demonstrate proper inhalation techniques of MDI.	Pharmacists' MDI demonstration technique was assessed by SP using a validated MDI checklist.

Study ID	Country	Study design	Setting	Study population	Sample size	Aim of the study	Outcomes measured and assessment method
<i>Hasan 2021</i> ³⁶	UAE	Observational study using SP who presented to the pharmacy and requested symptom relief from uncontrolled asthma.	Community pharmacies in Abu-Dhabi, Dubai, Sharjah and Ajman	Registered pharmacists	195 pharmacists (81 in Abu-Dhabi, 50 in Dubai, 49 in Sharjah, 15 in Ajman)	The study aimed to evaluate community pharmacists' ability to assess asthma control, compliance, and complications and to offer asthma management and advice to patients	SPs documented their visit to the pharmacy using data collection form to document the content of the visit in terms of pharmacists assessment of asthma control (history of asthma and current medications for asthma and other LTC****), compliance (regular use of preventer inhaler and inhaler technique), assessment of complications of asthma symptoms, pharmacist management (prescribing medication or referral to a physician) and advice giving on asthma management and medication use.
<i>Khan 2013</i> ⁴⁰	KSA	Observational study using SP who presented to the pharmacy with a friend asking them to train them on how to use MDI.	Community pharmacies in KSA in Alahsa region	Registered Pharmacists	71 pharmacists	The study aimed to assess community pharmacist's skills in MDI inhalation technique	Pharmacists' MDI demonstration technique was assessed by SP's friend using a published MDI checklist.
<i>Alghadeer 2015</i> ³⁹	KSA	Cross-sectional survey	Government al Hospital and Community Pharmacy in Riyadh City	Registered pharmacists	298 (101 hospital pharmacists, 197 community pharmacists)	The study aimed to evaluate the knowledge and attitude toward asthma care in hospital and community pharmacy	Questionnaires from previous similar study ⁴¹ were used to evaluate pharmacists Asthma knowledge (including pharmacotherapy, pathophysiology, peak flow measurement and care planning) and asthma attitude (including the need for special training, health impact of asthma, autonomy of patients, value of close monitoring, and role of pharmacists in asthma care).
<i>Alotaibi 2016</i> ³⁸	KSA	Cross-sectional survey	Community pharmacies in AL-Dwadmi region in Riyadh	Registered pharmacists	20 pharmacists	The study aimed to assess pharmacists' attitude towards asthma patients and their knowledge in terms of asthma management, their inhalation technique and asthma advice given to patients	Structured face-to-face questionnaire (from a previously published study). The questions assessed if pharmacists provide education to patients in terms of asthma pathophysiology, management plan, asthma medication and inhaler technique. Additionally, the questions assessed factors affecting pharmacists' ability to provide asthma advice to patients.

Abbreviations: *TH (Turbohaler), ACC (Accuhaler), MDI (Metered Dose Inhaler), **ACT (Asthma Control Test), PEF (Peak expiratory Flow), FEV (Forced expiratory Volume), ***SP (Simulated Patient), ****LTC (Long-term condition)

262 Study design and quality (objective 1).

263 The only RCT ³⁴ included was single-blinded, potentially reducing bias from participants in the
264 assessment of the intervention's effectiveness ⁴². This study was conducted in asthma patients
265 who were recruited from a single hospital, which may affect the generalisability of the results.
266 Patients were randomised into intervention and control groups and outcomes were measured
267 at baseline and after one-month of receiving the intervention ³⁴. This might be a limitation for
268 this study because it aimed to measure the effectiveness of the provided intervention in
269 maintaining correct inhaler technique among the study participants.

270 Four of the studies ^{35-37,40} used simulated patients (SPs) in data collection to observe the
271 pharmacists' skills and/or their ability to demonstrate correct inhaler technique. In three studies
272 ^{36,37,40}, pharmacy students and lay people with no health experience played the role of asthma
273 patients after being trained. Additionally, the training provided to the SPs should be reported
274 ^{43,44}, however, this was missing in one of the studies ³⁵.

275 Self-reported cross-sectional surveys were used in the two remaining studies ^{38,39}. Besides
276 the risk of social desirability bias and memory recalls, one of the studies did not mention
277 whether the used questionnaire was validated. Another study employed a survey that included
278 only yes/no questions, potentially increasing the risk of social desirability bias ³⁸.

279 One study had a very small sample ³⁸ and both were limited in terms of their setting ^{38,39} - one
280 was conducted inside Riyadh city in KSA ³⁸ and the other ³⁹ was in governmental hospitals
281 and pharmacies only.

282 Overall, the design and quality of the included studies was variable, and the limited settings
283 and samples reduce the ability to generalise their findings to the country in which they were
284 conducted, let alone to other GCC countries.

285 Interventions (Objective 2)

286 Only one RCT ³⁴ conducted in the UAE evaluated a pharmacist-led intervention. The
287 participants were classified into three groups depending on which inhaler they were using ³⁴.
288 Asthma patients were randomised into either a control group, who were provided with an
289 educational intervention session, or an active intervention group who were provided with the
290 session plus a label for their inhaler ³⁴.

291 The RCT ³⁴ suggested that inhaler technique training provided by the pharmacist to asthma
292 patients using Turbohaler (TH), Accuhaler (ACC) and pressurised Metered Dose Inhalers
293 (pMDI) in community pharmacies improved their inhaler technique. There was improvement
294 in asthma control level after receiving the intervention in patients using TH and pMDI but not
295 ACC, however, the number of patients using different devices was not equal and this may
296 have affected the results. Also, the study showed that using a personalised image label
297 attached to the inhaler can help patients maintain correct inhaler technique for a month.

298 Role of the pharmacist

299 In the intervention, the pharmacist used a "show and tell" approach to optimise inhaler
300 technique in all study participants ³⁴. They relied on a device-specific checklist to describe and
301 demonstrate the correct use of the inhaler. Additionally, for the active intervention group, the
302 pharmacist provided an Inhaler Technique Image label, highlighting any incorrect steps from
303 each patient's baseline assessment that were attached to the participant's inhaler device ³⁴.

304 *Training for pharmacists*

305 The pharmacist who delivered the intervention was a researcher³⁴ and the authors did not
306 report the training that was provided to the pharmacist before delivering the intervention.

307 ***Pharmacist's Knowledge (Objective 3)***

308 Six^{35-40,45} of the included studies assessed pharmacists' knowledge and skills in providing
309 asthma care.

310 *Asthma inhalation technique*

311 Two Saudi studies^{35,40} assessed pharmacists' ability to demonstrate the MDI inhalation
312 technique using reports from SPs. The two studies^{35,40} suggested that most pharmacists were
313 not able to demonstrate proper MDI inhalation technique. Only 7.3% (n= 7/96) of the
314 participating pharmacists in Al-Qasim region demonstrated proper inhaler technique³⁵ and
315 participating pharmacists from the Al-Ahsa region scored a mean of 4.2 out of 9 for their
316 inhalation technique demonstration using MDI checklist⁴⁰. Better MDI inhalation technique
317 was demonstrated by pharmacists with three to five years of experience working in a chain
318 pharmacy compared to those with less or more years of experience working in chain and
319 independent pharmacies⁴⁰. In Qatar, only one pharmacist out of 65 was able to demonstrate
320 correct inhaler technique to the SP³⁷.

321 *Asthma management*

322 Three studies^{36,38,39} assessed pharmacists' knowledge and/or attitude toward asthma
323 management. The first study³⁹ used an existing questionnaire to assess pharmacists'
324 knowledge of asthma pharmacotherapy, pathophysiology, peak flow monitoring and care
325 planning. The study also assessed pharmacists' attitudes toward the need for special training,
326 impact of asthma, autonomy of asthma patients, value of close monitoring and role of
327 pharmacists in asthma care³⁹. The second study³⁸ assessed pharmacists' attitudes toward
328 providing education on the pathophysiology of asthma and asthma care planning using a
329 previously developed questionnaire. Also, they asked pharmacists if they provided education
330 to patients on how to use their inhalers³⁸. Finally, the observational study in the UAE³⁶
331 assessed pharmacists' skills in assessing asthma control, compliance and complications and
332 providing asthma management advice to the patient, again using an SP approach to observe
333 the pharmacists' skills when being asked for a cough medication by a patient with asthma³⁶.

334 The Qatari study³⁷ assessed pharmacists' "counselling score" using SPs who presented to
335 the pharmacy with a new asthma prescription or for a refill of existing asthma medication. A
336 form was used to assess whether the pharmacist obtained information on patients' medical
337 history and medication use, and asked medication counselling specific questions³⁷.

338 In UAE and Qatar, the two studies^{36,37} assessing pharmacists' knowledge suggested that
339 community pharmacists may need to improve their knowledge about assessment of asthma
340 control, medication use and the provision of asthma management advice, including referral to
341 the GP. Only one out of 195 pharmacists in UAE asked the SPs about their medication use
342 when presenting to the pharmacy complaining of cough at night (a key sign of uncontrolled
343 asthma)³⁶. Additionally, the UAE study showed that pharmacists in independent compared to
344 chain pharmacies provided better advice on asthma management, however, there were no
345 data if the years of experience of participating pharmacists affected the results³⁶. Although
346 the study in Qatar³⁷ was conducted with only 65 pharmacists, it suggested that those with a
347 Master's degree provided better counselling to their patients in terms of advice on asthma
348 management and medications than those without.

349 The findings from the four studies ^{35-37,40} discussed above suggest a need to improve
350 pharmacists' knowledge of inhaler technique demonstration (mainly MDI), asthma
351 management advice and assessment of asthma control and medication use, in-line with
352 findings from the cross-sectional survey conducted in KSA. In this study, pharmacists showed
353 poor knowledge in terms of asthma pathophysiology and 97% (289/298) of pharmacists in
354 community and hospital settings reported that they needed training on asthma management
355 and advice ³⁹. However, another cross-sectional study in KSA showed that pharmacists
356 believed they had sufficient knowledge of asthma management and advice, and were
357 providing all aspects of asthma management to their patients including proper education about
358 inhaler technique ³⁸. This contradicts the two observational studies in KSA ^{35,40}.

359 ***Factors reported as affecting implementation (objective 4)***

360 The survey study in KSA ³⁸ and SP study in Qatar ³⁷ explored factors affecting the ability of
361 pharmacists to provide asthma patients with proper asthma education, care planning and/or
362 asthma management and medication advice. Both suggested that time is the main
363 limitation^{37,38}, although 40% of pharmacists surveyed in the Saudi study thought that it was
364 not their role to provide patient counselling to improve asthma control ³⁸. The Qatari study
365 related the sub-optimal asthma counselling among participating pharmacists to the lack of
366 education from the universities they graduated from, which were mainly in Egypt and India ³⁷.
367 Some pharmacy schools focus their curriculum on pharmaceutical sciences more than
368 pharmacy practice and patient care, affecting pharmacists' counselling skills and abilities ³⁷.
369 Additionally, some pharmacists reported they did not provide patient education because it is
370 not required by law in Qatar and/or saw it as the GP's role ³⁷.

371 Pharmacists surveyed in Qatar ³⁷ also highlighted a lack of patient interest in being educated
372 as a barrier to counselling in community pharmacies. In contrast, the RCT ³⁴ testing the inhaler
373 technique training intervention reported that no asthma patients withdrew from the study. The
374 authors suggest this might be because asthma patients appreciated the intervention provided
375 ³⁴.

376 Furthermore, the study in Qatar highlighted gender as a cultural barrier to providing education
377 in community pharmacy, finding that pharmacists tended to provide counselling to male
378 patients more often than females, especially females wearing a burqa ³⁷.

379 **Discussion**

380 Given that a significant number of asthma patients have poorly controlled asthma ^{5,6,15-17},
381 accessible interventions providing inhaler technique training, medication adherence support,
382 and advice on management are of considerable importance ^{5,9,10}. In the GCC countries, our
383 stakeholder group advised that while individual pharmacists may make isolated efforts to
384 provide patient education or inhaler technique training, routine and scalable patient education
385 activities are not consistently implemented. Conducting this review, we found a limited number
386 of studies on the role of pharmacists in asthma care in the GCC countries. This review
387 summarises the literature on pharmacist-led asthma interventions provided to adults and
388 pharmacists' knowledge of asthma management in the GCC countries.

389 ***Current evidence on the potential role of pharmacists in asthma care***

390 This review included only one study ³⁴ that evaluated a pharmacist-led asthma intervention in
391 the UAE. The RCT ³⁴ showed a promising role for pharmacists in asthma care mainly in
392 providing inhaler technique training intervention in community pharmacy. Pharmacist-led
393 educational interventions were also found to improve asthma patients' inhaler technique,

394 asthma control and use of reliever inhalers in studies in Jordan, another Middle Eastern
395 country^{46,47}. Although pharmacists are readily accessible HCPs and have been shown in other
396 studies to provide cost-effective educational interventions on inhaler technique^{19,48-52}, one
397 study that included participants from a single governmental hospital in Dubai is insufficient
398 evidence to demonstrate the effectiveness of pharmacist-led asthma interventions in
399 community pharmacy in Dubai or other cities in the UAE³⁴ and highlights the need for more
400 research on extending the role of pharmacists in asthma interventions across the GCC
401 countries. More research could be conducted over a long period, in different locations in UAE
402 and larger sample size. However, the study showed that using a structured approach in
403 providing patient education in community pharmacy might allow for consistency in delivering
404 asthma care in community pharmacy.

405 We also reviewed studies that assessed pharmacists' knowledge and skills related to asthma
406 and asthma management to provide insights into pharmacists' potential ability to provide
407 asthma interventions in the GCC countries. These studies utilised SP^{35-37,40} and cross-
408 sectional survey^{38,39} designs, sometimes using non-validated tools, which were of variable
409 quality and limited in terms of the generalisability of their results as they were conducted in
410 single regions or small samples. Additionally, there was potential risk of social desirability bias
411 that was not taken into consideration and this was reflected in the results³⁸ when we compared
412 to results from other studies^{35,40}. Therefore, findings should be interpreted with caution.
413 However, summarising findings from these studies helped highlight the needs for pharmacists'
414 training in hospital and community settings. The review suggests the need for better education
415 and training in inhaler technique demonstration (mainly MDI) and assessment of asthma
416 control and asthma medication use. Generally, there is a need to provide regular refreshers to
417 update pharmacists' knowledge on asthma management^{52,53}. This is in-line with a cross-
418 sectional survey conducted in Egypt, which showed inadequate knowledge and practices of
419 asthma management among pharmacists in community and hospitals⁵³. Pharmacists were
420 also identified among the HCPs who require further education on inhaled medication use
421 globally^{51,54}. A further observational and cross-sectional survey study involving 45 community
422 pharmacists in Canada⁵⁴ reported that 33% had not received proper education on inhaler
423 use, 44% received instructions from a pharmaceutical representative and 40% from
424 professional school. An Australian study⁵⁵ showed that 87% of 31 community pharmacists
425 participating in the study received education on inhaler use but two to four years before the
426 study, mainly by a pharmaceutical representative. Together with the review, these studies^{54,55}
427 highlight the need to provide education on inhaler technique and to maintain competence of
428 pharmacists in demonstrating the correct technique in the longer term.

429 Consistent with literature^{53,56,57}, this review also highlights a lack of confidence among
430 pharmacists in different countries in providing asthma management advice to their patients. In
431 one included study⁴⁰ pharmacists with more years of experience showed less knowledge and
432 skills compared to their colleagues with fewer years of experience, perhaps due to recent
433 changes to pharmacist training or a lack of continuous asthma education^{53,58}. In previous
434 studies, pharmacists showed positive attitudes towards learning and training on providing
435 management advice for asthma and other diseases, however, some pharmacists lacked
436 access to resources such as online training, books and professional conferences and reported
437 that they did not have time allocated to personal development^{56,57}. In one study in the review,
438 hospital pharmacists showed better knowledge of asthma management advice compared to
439 community pharmacists³⁹ in previous studies^{41,53}. This might be related to their role, which is
440 not limited to dispensing.

441 This review suggests a lack of pharmacists' awareness of their role in asthma management
442 as reported in the findings from two included studies in Qatar³⁷ and KSA³⁸. This agrees with

443 a previous study⁵⁸ that explored pharmacists' perception of their role in asthma management
444 in Canada. This study⁵⁸ also highlighted that pharmacists may underestimate the severe
445 consequences of uncontrolled asthma on the patients. A lack of understanding and diverse
446 perceptions of pharmacists' roles in providing pharmaceutical care in general, not only in
447 asthma, was evident in previous studies from Qatar^{59,60}.

448 ***Challenges faced by pharmacists in providing asthma care***

449 Besides the need to train pharmacists on asthma management, the review identified factors
450 that should be taken into consideration when developing and implementing any pharmacist-
451 led asthma intervention or initiative. In all GCC countries from which the studies were
452 identified, time was considered a main barrier to the provision of care to asthma patients^{59,61-}
453⁶³. The lack of time in community pharmacies, possibly related to staffing, has been
454 emphasised in international studies discussing barriers to expanding the role of pharmacists
455 in asthma care and management^{19,52,58}. Therefore, before involving pharmacists in providing
456 new services there might be a need to increase the number of competent staff to maintain
457 high quality services. There may also be a need to enhance competency of community
458 pharmacists to ensure that they can provide management advice to asthma patients, as shown
459 in this review and for patients with other LTCs^{31,60,61,64,65}. There is a lack of evidence regarding
460 the relationship between the pharmacy curriculum at undergraduate level in the countries
461 where the studies were conducted and pharmacists' knowledge and skills, as most of the
462 pharmacists participating in the included studies completed their degrees in Egypt and India
463^{37,39}. This can be related to the insufficient number of pharmacy graduates in the GCC
464 countries, for example, only 11% of practising pharmacists in KSA are Saudi⁶⁶.

465 Another factor identified related to patients' attitudes towards receiving advice in community
466 pharmacy, including lack of interest and cultural barriers in some countries. Internationally,
467 several studies assessed public satisfaction and expectations regarding pharmacist-led
468 services or initiatives and showed positive attitudes among patients toward services in
469 community pharmacy. In the Middle East, many studies reported that the public perceived
470 pharmacists as "business or mere vendors of medications", which may reflect the absence of
471 pharmacist-led services beyond medication dispensing in these countries⁶⁵. There are some
472 negative public perceptions around the role of pharmacists and a lack of trusted relationships
473 between pharmacists and the public is considered a barrier to extending the pharmacists' role
474⁶⁵. This might reflect inadequate communication and time spent with pharmacists when
475 patients visit the pharmacy, or patients not being satisfied with the pharmacists' level of
476 knowledge⁶⁷.

477 Finally, another key factor that may negatively impact the provision of services in community
478 pharmacy is difficulties in identifying patients who may need the service^{56,59}. This reflects a
479 lack of patient records in community pharmacies not only in UAE^{18,61} and GCC countries^{68,69}
480 but also internationally, as seen in Malaysia⁷⁰, Jordan⁷¹ and the UK⁷². Although this was not
481 explicitly mentioned in the studies in this review, the intervention study³⁴, identified and
482 recruited patients in a hospital and then provided the intervention in a community pharmacy.
483 Such cross-organisation and multidisciplinary teamwork might help extend the role of
484 pharmacists and enhance equality in access of patients to adequate asthma care in the future.
485 However, as suggested by El Hajj and colleagues⁵⁹, there is a need to enhance pharmacists'
486 understanding of multidisciplinary team working and encourage all HCPs, including
487 pharmacists in different settings, to work as a team and not in silos.

488 **Implications for policy and practice**

489 Pharmacy practice is still in its infancy in GCC countries and requires a holistic approach that
490 involves collaborative efforts from academics, professional and regulatory bodies ^{31,60,66,73}.

491 With the increasing number of pharmacy schools in the GCC countries and initiatives to extend
492 pharmacists' role, there is a need to incorporate asthma training, pharmaceutical care and
493 pharmacy practice into pharmacy curricula to promote better practice, involve pharmacists in
494 the management plan for the patients and enhance competencies amongst staff to address
495 gaps in the provision of care ^{59,64}. Additionally, the establishment of an independent
496 professional organisation that represents pharmacists in UAE, Qatar and other GCC countries
497 might positively influence competency among pharmacists ¹⁸. As well as, enhancement of the
498 role of pharmacists associations that already exist, for example, in KSA ⁷⁴ and Kuwait ⁷³, in the
499 provision of training and education to pharmacists working in all settings. There could be
500 differences in the education provided across the countries in the Gulf, for example in Kuwait,
501 transformation of the initial education in pharmacy and the development of the foundation
502 training program for early career pharmacists were implemented to help pharmacists deliver
503 high quality care ⁷³. Operational factors including staffing and access to patients' information
504 also need to be taken into consideration by policy makers to facilitate the expansion of the role
505 of pharmacists in providing care and management to patients with asthma and other LTCs.

506 **Strength and limitations**

507 By shedding light on the existing body of knowledge in this region, this review endeavours to
508 bridge the gap in understanding the potential contributions and challenges faced by
509 pharmacists in improving the care and outcomes of adults living with asthma in the Gulf. The
510 review included studies with any design and in any setting to provide better insights on the
511 aim of the review by including as many studies as possible. However, the review identified
512 only seven studies, limiting the interpretation of the findings and the ability to compare the
513 quality of the included studies.

514 **Conclusions**

515 The review highlights a notable gap in research, specifically the absence of studies evaluating
516 pharmacist-led asthma interventions in adult patients in the GCC countries. The lack of robust
517 studies evaluating pharmacists' knowledge was evident in this review. Future research should
518 exercise greater rigour in terms of design and reporting to generate evidence that can be used
519 to inform policy and practice in pharmacy ⁷⁵ in GCC countries.

520 The review highlighted pharmacists training needs in terms of asthma management; mainly
521 inhaler technique demonstration. These training needs might be taken into consideration not
522 only in intervention development by researchers but also by policy makers and professional
523 bodies when developing and improving continuous training and education for pharmacists.
524 Additionally, academic institutions should consider these needs when developing pharmacy
525 curricula. Enhancement of competency among staff and launching pharmacist-led service that
526 is integrated into pharmacy workflow may positively influence the public perceptions of
527 pharmacists' role and trust in pharmacists in the GCC countries.

528 **References**

- 529 1. Royal College of Physicians. Why asthma still kills: The National Review of Asthma Deaths
530 (NRAD) Confidential Enquiry Report RCP. [https://www.rcplondon.ac.uk/projects/outputs/why-](https://www.rcplondon.ac.uk/projects/outputs/why-asthma-still-kills)
531 [asthma-still-kills](https://www.rcplondon.ac.uk/projects/outputs/why-asthma-still-kills).

- 532 2. World Health Organisation. Asthma Fact Sheet World Health Organisation WHO.
533 <http://www.who.int/mediacentre/factsheets/fs307/en/>.
- 534 3. Bahadori K, Doyle-Waters MM, Marra C, et al. Economic burden of asthma: a systematic
535 review. *BMC Pulm Med*. May 19 2009;9:24. doi:10.1186/1471-2466-9-24
- 536 4. Tarraf H, Aydin O, Mungan D, et al. Prevalence of asthma among the adult general population
537 of five Middle Eastern countries: results of the SNAPSHOT program. *BMC Pulmonary Medicine*.
538 2018/05/11 2018;18(1):68. doi:10.1186/s12890-018-0621-9
- 539 5. Al Busaidi N, Alweqayyan A, Zaabi A, et al. Gulf Asthma Diagnosis and Management in
540 Adults: Expert Review and Recommendations. *The Open Respiratory Medicine Journal*. 07/18
541 2022;16doi:10.2174/18743064-v16-e2205230
- 542 6. Khadadah M, Mahboub B, Al-Busaidi NH, Sliman N, Soriano JB, Bahous J. Asthma insights and
543 reality in the Gulf and the near East. *Int J Tuberc Lung Dis*. Aug 2009;13(8):1015-22.
- 544 7. British Thoracic Society and Scottish Intercollegiate Guidelines Network. British guideline on
545 the management of asthma; A national clinical guideline. *BTS and SIGN*. 2019;
- 546 8. Global Initiative for Asthma. Pocket guide for asthma management and prevention: GINA.
547 2019;
- 548 9. Asthma UK. Meet your asthma healthcare team. <https://www.asthma.org.uk/advice/nhs-care/healthcare>
- 549
- 550 10. National institute for Health and Care Excellence. Asthma: diagnosis, monitoring and chronic
551 asthma management. Updated 2020. [https://www.nice.org.uk/guidance/ng80/resources/asthma-](https://www.nice.org.uk/guidance/ng80/resources/asthma-diagnosis-monitoring-and-chronic-asthma-management-pdf-1837687975621)
552 [diagnosis-monitoring-and-chronic-asthma-management-pdf-1837687975621](https://www.nice.org.uk/guidance/ng80/resources/asthma-diagnosis-monitoring-and-chronic-asthma-management-pdf-1837687975621)
- 553 11. Department of Health. DoH Guidelines for the Initial Diagnosis and Management of Asthma
554 in adults (≥ 18 yrs) by Primary Healthcare Providers. Department of Health.
555 <file:///C:/Users/am1611/Downloads/DoH%20Guidelines%20for%20Asthma%20in%20adults.pdf>
- 556 12. Khaleej Times. Ministry of Health launches guidelines for asthma. www.khaleejtimes.com.
557 <https://www.khaleejtimes.com/health/ministry-of-health-launches-guidelines-for-asthma>
- 558 13. Al-Moamary MS, Al-Hajjaj MS, Idrees MM, et al. The Saudi Initiative for Asthma. *Ann Thorac*
559 *Med*. Oct 2009;4(4):216-33. doi:10.4103/1817-1737.56001
- 560 14. UAE Today. Ministry Of Health And Prevention Launches "Ea'nah" Initiative To Support
561 Patients With Multiple Sclerosis, Atopic Dermatitis And Severe Asthma. www.uaetoday.com.
562 https://www.uaetoday.com/news_details/72554/ministry-of-health-and-prevention-launches-
563
- 564 15. Alzaabi A, Idrees M, Behbehani N, et al. Cross-sectional study on Asthma Insights and
564 Management in the Gulf and Russia. *Allergy Asthma Proc*. Nov 16 2018;39(6):430-436.
565 doi:10.2500/aap.2018.39.4180
- 566 16. Tarraf H, Al-Jahdali H, Al Qaseer AH, et al. Asthma control in adults in the Middle East and
567 North Africa: Results from the ESMAA study. *Respir Med*. May 2018;138:64-73.
568 doi:10.1016/j.rmed.2018.03.024
- 569 17. Ibrahim WH, Suleiman NN, El-Allus F, et al. The burden of adult asthma in a high GDP per
570 capita country: the QASMA study. *Annals of Allergy, Asthma & Immunology*. 2015/01/01/
571 2015;114(1):12-17. doi:<https://doi.org/10.1016/j.anai.2014.08.014>
- 572 18. Hasan S, Sulieman H, Chapman CB, Stewart K, Kong DCM. Community pharmacy services in
573 the United Arab Emirates. *International Journal of Pharmacy Practice*. 2011;20(4):218-225.
574 doi:10.1111/j.2042-7174.2011.00182.x
- 575 19. Bridgeman MB, Wilken LA. Essential Role of Pharmacists in Asthma Care and Management. *J*
576 *Pharm Pract*. Feb 2021;34(1):149-162. doi:10.1177/0897190020927274
- 577 20. Taqi A, Rowlands G, Rathbone AP. A systematic review and thematic synthesis to identify
578 factors that influence pharmacists' involvement in asthma care services: An identity crisis. *Explor Res*
579 *Clin Soc Pharm*. Sep 2021;3:100051. doi:10.1016/j.rcsop.2021.100051
- 580 21. Bloom CI, Ramsey H, Alter M, et al. Qualitative Study of Practices and Challenges of Stepping
581 Down Asthma Medication in Primary Care Across the UK. *J Asthma Allergy*. 2020;13:429-437.
582 doi:10.2147/jaa.S274943

- 583 22. Marissa Ayano M, Caroline Brigitte K, Vari W, Amy Hai Yan C, Robert H, Stephanie Jane
584 Caroline T. Pharmacist-led adherence support in general practice: a qualitative interview study of
585 adults with asthma. *BMJ Open*. 2019;9(11):e032084. doi:10.1136/bmjopen-2019-032084
586 23. Pharmaceutical Services Negotiating Committee. Community pharmacy and the
587 management of people with asthma. [https://psnc.org.uk/services-commissioning/locally-](https://psnc.org.uk/services-commissioning/locally-commissioned-services/asthma/)
588 [commissioned-services/asthma/](https://psnc.org.uk/services-commissioning/locally-commissioned-services/asthma/).
- 589 24. Attar-Zadeh D. UK asthma mortality is too high, but pharmacy can help. Article. *Clinical*
590 *Pharmacist*. 2019;11(2)doi:10.1211/CP.2019.20206055
- 591 25. Brown D, Portlock J, Rutter P. Review of services provided by pharmacies that promote
592 healthy living. Review. *International Journal of Clinical Pharmacy*. 2012;34(3):399-409.
593 doi:10.1007/s11096-012-9634-2
- 594 26. Pharmaceutical Services Negotiating Committee. New Medicine Service (NMS). PSNC.
595 <http://psnc.org.uk/servicescommissioning/advanced-services/nms/>
596 27. Committee. PSN. PSNC Briefing 042/19: Pharmacy Quality Scheme – Asthma referrals
597 [https://psnc.org.uk/wp-content/uploads/2019/10/PSNC-Briefing-042.19-Pharmacy-Quality-Scheme-](https://psnc.org.uk/wp-content/uploads/2019/10/PSNC-Briefing-042.19-Pharmacy-Quality-Scheme-Asthma-referrals.pdf)
598 [Asthma-referrals.pdf](https://psnc.org.uk/wp-content/uploads/2019/10/PSNC-Briefing-042.19-Pharmacy-Quality-Scheme-Asthma-referrals.pdf).
- 599 28. Mahmoud A, Mullen R, Penson PE, Morecroft C. The management of asthma in adult
600 patients in the community pharmacy setting: Literature review. *Research in Social and Administrative*
601 *Pharmacy*. 2021/11/01/ 2021;17(11):1893-1906. doi:<https://doi.org/10.1016/j.sapharm.2021.04.001>
- 602 29. Craske M, Wright D, Blacklock J, et al. Testing annual asthma reviews for those who fail to
603 attend: proof-of-concept study. *The Pharmaceutical Journal*. 2018;8(10):243-249.
- 604 30. Garcia-Cardenas V, Armour C, Benrimoj SI, Martinez-Martinez F, Rotta I, Fernandez-Llimos F.
605 Pharmacists' interventions on clinical asthma outcomes: a systematic review. *Eur Respir J. Apr*
606 2016;47(4):1134-43. doi:10.1183/13993003.01497-2015
- 607 31. Sadek MM, Elnour AA, Al Kalbani NMS, et al. Community pharmacy and the extended
608 community pharmacist practice roles: The UAE experiences. *Saudi Pharmaceutical Journal*.
609 2016/09/01/ 2016;24(5):563-570. doi:<https://doi.org/10.1016/j.jsps.2015.03.023>
- 610 32. Peters MDJ, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB. Guidance for conducting
611 systematic scoping reviews. *JBI Evidence Implementation*. 2015;13(3)
- 612 33. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR):
613 Checklist and Explanation. *Annals of Internal Medicine*. 2018/10/02 2018;169(7):467-473.
614 doi:10.7326/M18-0850
- 615 34. Basheti I, Mahboub B, Salameh L, et al. Assessment of Novel Inhaler Technique Reminder
616 Labels in Image Format on the Correct Demonstration of Inhaler Technique Skills in Asthma: A Single-
617 Blinded Randomized Controlled Trial. *Pharmaceuticals*. 2021;14(2):12.
- 618 35. Adnan M, Karim S, Khan S, Al-Wabel NA. Comparative evaluation of metered-dose inhaler
619 technique demonstration among community pharmacists in Al Qassim and Al-Ahsa region, Saudi-
620 Arabia. *Saudi Pharmaceutical Journal*. 2015;23(2):138-42.
- 621 36. Hasan S, Al Oum L, Hassan NA. A simulated patient study to evaluate community pharmacist
622 assessment, management and advice giving to patients with asthma. *Journal of Pharmaceutical*
623 *Policy & Practice*. 2021;14(1):8.
- 624 37. Paravattil B, Kheir N, Yousif A. Utilization of simulated patients to assess diabetes and asthma
625 counseling practices among community pharmacists in Qatar. *International Journal of Clinical*
626 *Pharmacy*. 2017;39(4):759-768.
- 627 38. Alotaibi HS, Shivanandappa TB, Nagarethinam S. Contribution of community pharmacists in
628 educating the asthma patients. *Saudi Pharmaceutical Journal*. 2016;24(6):685-688.
- 629 39. Alghadeer SM, Mayet AY, Babelghaith SD, et al. Evaluation of knowledge and attitude
630 towards asthma care in hospital and community pharmacy settings at central Saudi Arabia.
631 *International Journal of Green Pharmacy*. 2015;9(4 Supplement):S79-S85.

- 632 40. Khan TM, Azhar S. A study investigating the community pharmacist knowledge about the
633 appropriate use of inhaler, Eastern Region AlAhsa, Saudi Arabia. *Saudi Pharm J.* Apr 2013;21(2):153-
634 7. doi:10.1016/j.jsps.2012.07.004
- 635 41. Chiang YC, Lee CN, Lin YM, Yen YH, Chen HY. Impact of a continuing education program on
636 pharmacists' knowledge and attitudes toward asthma patient care. *Med Princ Pract.* 2010;19(4):305-
637 11. doi:10.1159/000312718
- 638 42. Monaghan TF, Agudelo CW, Rahman SN, et al. Blinding in Clinical Trials: Seeing the Big
639 Picture. *Medicina (Kaunas).* Jun 24 2021;57(7)doi:10.3390/medicina57070647
- 640 43. Collins JC, Chong WW, de Almeida Neto AC, Moles RJ, Schneider CR. The simulated patient
641 method: Design and application in health services research. *Research in Social and Administrative
642 Pharmacy.* 2021/12/01/ 2021;17(12):2108-2115. doi:https://doi.org/10.1016/j.sapharm.2021.04.021
- 643 44. Björnsdóttir I, Granas AG, Bradley A, Norris P. A systematic review of the use of simulated
644 patient methodology in pharmacy practice research from 2006 to 2016. *International Journal of
645 Pharmacy Practice.* 2020;28(1):13-25.
- 646 45. Baddar SA, Al-Rawas OA, Al-Riyami KA, et al. Metered-dose inhaler technique among
647 healthcare providers practising in Oman. Article. *Sultan Qaboos University Medical Journal.*
648 2000;3(1):39-43.
- 649 46. Al-Awaisheh RI, Alsayed AR, Basheti IA. Assessing the Pharmacist's Role in Counseling
650 Asthmatic Adults Using the Correct Inhaler Technique and Its Effect on Asthma Control, Adherence,
651 and Quality of Life. *Patient Prefer Adherence.* 2023;17:961-972. doi:10.2147/ppa.S395258
- 652 47. Basheti IA, Salhi YB, Basheti MM, Hamadi SA, Al-Qerem W. Role of the pharmacist in
653 improving inhaler technique and asthma management in rural areas in Jordan. *Clin Pharmacol.*
654 2019;11:103-116. doi:10.2147/cpaa.S213271
- 655 48. Petite SE, Hess MW, Wachtel H. The Role of the Pharmacist in Inhaler Selection and
656 Education in Chronic Obstructive Pulmonary Disease. *J Pharm Technol.* Apr 2021;37(2):95-106.
657 doi:10.1177/8755122520937649
- 658 49. Rossi V, Salimäki J, Sandler C, Airaksinen M, Kauppi P. Effectiveness of inhalation technique
659 assessment service for patients with Respimat® inhaler. *Pulmonary Pharmacology & Therapeutics.*
660 2021/12/01/ 2021;71:102077. doi:https://doi.org/10.1016/j.pupt.2021.102077
- 661 50. Mil JWFv. *Pharmaceutical care, the future of pharmacy: theory, research, and practice.* The
662 University of Groningen; 2000. https://pure.rug.nl/ws/portalfiles/portal/14524956/thesis.pdf
- 663 51. Pronk M, Blom L, Jonkers R, Bakker A. Community pharmacy and patient-oriented activities:
664 the Dutch case. *Patient Education and Counseling.* 2002/01/01/ 2002;46(1):39-45.
665 doi:https://doi.org/10.1016/S0738-3991(01)00148-3
- 666 52. Bollmeier SG, Prosser TR. Community pharmacy-based asthma services: current perspectives
667 and future directions. *Integrated Pharmacy Research and Practice.* 2014/08/11 2014;3(null):49-70.
668 doi:10.2147/IPRP.S47331
- 669 53. Said ASA, Hussain N, Kharaba Z, Al Haddad AHI, Abdelaty LN, Hussein RRS. Knowledge,
670 attitude, and practice of pharmacists regarding asthma management: a cross-sectional study in
671 Egypt. *J Pharm Policy Pract.* May 3 2022;15(1):35. doi:10.1186/s40545-022-00432-0
- 672 54. Kesten S, Zive K, Chapman KR. Pharmacist knowledge and ability to use inhaled medication
673 delivery systems. *Chest.* Dec 1993;104(6):1737-42. doi:10.1378/chest.104.6.1737
- 674 55. Basheti IA, Armour CL, Reddel HK, Bosnic-Anticevich SZ. Long-term maintenance of
675 pharmacists' inhaler technique demonstration skills. *Am J Pharm Educ.* Apr 7 2009;73(2):32.
676 doi:10.5688/aj730232
- 677 56. Seston EM, Anoliefo CJ, Guo J, et al. Community Pharmacist Consultation Service: A Survey
678 Exploring Factors Facilitating or Hindering Community Pharmacists' Ability to Apply Learnt
679 Skills in Practice. *Pharmacy.* 2022;10(5). doi:10.3390/pharmacy10050117
- 680 57. Aldosari H, Alsairafi Z, Waheedi S. Continuing education in pharmacy: A cross-sectional study
681 exploring pharmacists' attitudes and perceptions. *Saudi Pharm J.* Jul 2020;28(7):803-813.
682 doi:10.1016/j.jsps.2020.05.008

- 683 58. Nadaira N, Ouellet C, René-Henri N, et al. Factors Influencing a Community Pharmacist's
684 Interventions in Asthma Care. *Canadian Pharmacists Journal / Revue des Pharmaciens du Canada*.
685 2009;142:240 - 246.
- 686 59. El Hajj MS, Al-Saeed HS, Khaja M. Qatar pharmacists' understanding, attitudes, practice and
687 perceived barriers related to providing pharmaceutical care. *Int J Clin Pharm*. Apr 2016;38(2):330-43.
688 doi:10.1007/s11096-016-0246-0
- 689 60. Al-Sulaiti F, Fares H, Awaisu A, Kheir N. Continuing Professional Development Needs of
690 Community Pharmacists in Qatar: A Mixed-Methods Approach. *Int Q Community Health Educ*. Apr
691 2021;41(3):285-292. doi:10.1177/0272684x20918048
- 692 61. Ghazal RM. Barriers to the implementation of Pharmaceutical Care into the UAE community
693 pharmacies. *IOSR Journal of Pharmacy*. 2014;04:68-74.
- 694 62. Rasheed MK, Hasan SS, Babar Z-U-D. Community pharmacist's knowledge, attitude, roles and
695 practices towards patient-centred care in Saudi Arabia: a systematic review of the literature. *Journal*
696 *of Pharmaceutical Health Services Research*. 2019;10(1):101-115. doi:10.1111/jphs.12264
- 697 63. Lemay J, Waheedi M, Al-Taweel D, Bayoud T, Moreau P. Clinical pharmacy in Kuwait: Services
698 provided, perceptions and barriers. *Saudi Pharm J*. May 2018;26(4):481-486.
699 doi:10.1016/j.jsps.2018.02.011
- 700 64. Abusham AA, Aljuma MA, Ali LA, Riyami QAA. Pharmacy education in the Sultanate of Oman:
701 Challenges and opportunities. *Pharmacy Education*. 2022;
- 702 65. El Hajj MS, Mekkawi R, Elkaffash R, Saleh R, El Awaisi A, Wilbur K. Public attitudes towards
703 community pharmacy in Arabic speaking Middle Eastern countries: A systematic review. *Research in*
704 *Social and Administrative Pharmacy*. 2021/08/01/ 2021;17(8):1373-1395.
705 doi:https://doi.org/10.1016/j.sapharm.2020.11.013
- 706 66. Kheir N, Zaidan M, Younes H, El Hajj M, Wilbur K, Jewesson PJ. Pharmacy education and
707 practice in 13 Middle Eastern countries. *Am J Pharm Educ*. Dec 15 2008;72(6):133.
708 doi:10.5688/aj7206133
- 709 67. El Hajj MS, Salem S, Mansoor H. Public's attitudes towards community pharmacy in Qatar: a
710 pilot study. *Patient Prefer Adherence*. 2011;5:405-22. doi:10.2147/ppa.S22117
- 711 68. Shami R, Alam MF, ElHajj MS. The role of community pharmacists in depression
712 management: a survey of attitudes, practices and perceived barriers. *Int J Clin Pharm*. Feb
713 2022;44(1):214-226. doi:10.1007/s11096-021-01337-9
- 714 69. AlMukdad S, Zaghoul N, Awaisu A, Mahfoud ZR, Kheir N, El Hajj MS. Exploring the Role of
715 Community Pharmacists in Obesity and Weight Management in Qatar: A Mixed-Methods Study. *Risk*
716 *Manag Healthc Policy*. 2021;14:2771-2787. doi:10.2147/rmhp.S309142
- 717 70. Loh P, Chua SS, Karuppanan M. The extent and barriers in providing pharmaceutical care
718 services by community pharmacists in Malaysia: a cross-sectional study. *BMC Health Serv Res*. Aug 16
719 2021;21(1):822. doi:10.1186/s12913-021-06820-7
- 720 71. AbuRuz S, Al-Ghazawi M, Snyder A. Pharmaceutical care in a community-based practice
721 setting in Jordan: where are we now with our attitudes and perceived barriers? *International Journal*
722 *of Pharmacy Practice*. 2012;20(2):71-79. doi:10.1111/j.2042-7174.2011.00164.x
- 723 72. Wright D. *A rapid review of evidence regarding clinical services commissioned from*
724 *community pharmacies*. 2016.
- 725 73. Al-Haqan A, Moreau P, Alghanem S, et al. Transforming pharmacy practice in Kuwait. *The*
726 *International Journal of Health Planning and Management*. 2023/07/01 2023;38(4):879-888.
727 doi:https://doi.org/10.1002/hpm.3631
- 728 74. The Saudi Pharmaceutical Society (SPS). <https://www.sipa-sps.com/about-us>
- 729 75. Awaisu A, Mukhalalati B, Mohamed Ibrahim MI. *Research Designs and Methodologies*
730 *Related to Pharmacy Practice*. Encyclopedia of Pharmacy Practice and Clinical Pharmacy. 2019:7-21.
731 doi: 10.1016/B978-0-12-812735-3.00602-6. Epub 2019 Jul 23.